Stock Research for CGEN

CGEN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CGEN Stock Chart & Research Data

The CGEN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CGEN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CGEN Due diligence Resources & Stock Charts

The CGEN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CGEN Detailed Price Forecast - CNN Money CNN View CGEN Detailed Summary - Google Finance
Yahoo View CGEN Detailed Summary - Yahoo! Finance Zacks View CGEN Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View CGEN Trends & Analysis - Trade-Ideas Barrons View CGEN Major Holders - Barrons
NASDAQ View CGEN Call Transcripts - NASDAQ Seeking View CGEN Breaking News & Analysis - Seeking Alpha
Spotlight View CGEN Annual Report - CompanySpotlight.com OTC Report View CGEN OTC Short Report - OTCShortReport.com
TradeKing View CGEN Fundamentals - TradeKing Charts View CGEN SEC Filings - Bar Chart
WSJ View Historical Prices for CGEN - The WSJ Morningstar View Performance/Total Return for CGEN - Morningstar
MarketWatch View the Analyst Estimates for CGEN - MarketWatch CNBC View the Earnings History for CGEN - CNBC
StockMarketWatch View the CGEN Earnings - StockMarketWatch MacroAxis View CGEN Buy or Sell Recommendations - MacroAxis
Bullish View the CGEN Bullish Patterns - American Bulls Short Pains View CGEN Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View CGEN Stock Mentions - StockTwits PennyStocks View CGEN Stock Mentions - PennyStockTweets
Twitter View CGEN Stock Mentions - Twitter Invest Hub View CGEN Investment Forum News - Investor Hub
Yahoo View CGEN Stock Mentions - Yahoo! Message Board Seeking Alpha View CGEN Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for CGEN - SECform4.com Insider Cow View Insider Transactions for CGEN - Insider Cow
CNBC View CGEN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CGEN - OTC Markets
Yahoo View Insider Transactions for CGEN - Yahoo! Finance NASDAQ View Institutional Holdings for CGEN - NASDAQ


Stock Charts

FinViz View CGEN Stock Insight & Charts - FinViz.com StockCharts View CGEN Investment Charts - StockCharts.com
BarChart View CGEN Stock Overview & Charts - BarChart Trading View View CGEN User Generated Charts - Trading View




Latest Financial News for CGEN


Compugen Second Quarter 2018 Conference Call Scheduled for Wednesday, August 1, 2018 at 8:30 AM ET
Posted on Wednesday July 18, 2018

HOLON, Israel , July 18, 2018 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company ...


Benzinga Pro's 5 Stocks To Watch Today
Posted on Monday July 02, 2018

Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Alkermes Plc (NASDAQ: ALKS ) stock was trading higher ...


Compugen Welcomes FDA Clearance of Bayer's IND Application for BAY 1905254
Posted on Monday July 02, 2018

HOLON, Israel, July 2, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN) (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, was informed that the U.S. Food and Drug Administration (FDA) has cleared Bayer AG's investigational new drug (IND) application for BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting the ILDR2 protein in patients with advanced solid tumors. ILDR2 is a novel immune checkpoint discovered by Compugen through its predictive computational capabilities, which enable the discovery of new drug targets and biological pathways.


Compugen Announces FDA Clearance of IND Application for COM701, a First-in-class Immuno-Oncology Therapeutic Antibody
Posted on Monday July 02, 2018

Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on its investigational new drug (IND) application for COM701, a first-in-class immuno-oncology therapeutic antibody targeting PVRIG in patients with advanced solid tumors, and informed the Company it may initiate the clinical study. "Today is a significant milestone for Compugen, having received clearance from the FDA to advance our lead immuno-oncology program into the clinic. COM701 is a first-in-class drug opportunity that was developed by Compugen from discovery of the drug target by computer prediction through preclinical development, to IND clearance," stated Anat Cohen-Dayag, PhD, President and CEO of Compugen.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.